Vitamin B12 injection passes generic drug consistency evaluation
November 2, 2026
Source: drugdu
28
Nancai Intelligence News, October 30th - Haixin Co., Ltd.The announcement states that its controlling subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., received the "Approval Notice for Supplemental Drug Application" issued by the National Medical Products Administration, authorizing the production of vitamins .B12 injection has passed the consistency evaluation for generic drug quality and efficacy. This drug is primarily used for megaloblastic anemia caused by intrinsic factor deficiency, and can also be used as an adjunct treatment for subacute combined degenerative neurological disorders. According to the Moshang Pharmaceutical Database, the sales of this drug in medical institutions and physical pharmacies in 2025 were 84.76 million yuan. Passing this evaluation will help enhance the product's market competitiveness but will not have a significant impact on the company's current operating performance.
Source: https://finance.eastmoney.com/a/202610303916433870.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Wolwo Pharma’s S01D Tablet Approved for Clinical Trials, a New-Mechanism Drug for Drug-Resistant Pulmonary Tuberculosis November 2, 2026
- Two specifications of dexketoprofen tromethamine tablets from Keruide Pharmaceuticals have been approved November 2, 2026
- Another domestically produced biopharmaceutical has entered the European market; Qilu Pharmaceutical’s bevacizumab has been shipped to the UK. November 2, 2026
- Nemonoxacin malate has been approved for registration as an active pharmaceutical ingredient in marketed pharmaceutical preparations. November 2, 2026
- Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting October 29, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
